Literature DB >> 7144217

Exsanguinating hemoptysis.

A A Garzon, M M Cerruti, M E Golding.   

Abstract

Massive hemoptysis (600 ml in 24 hours) results in a mortality of more than 50%. We have performed 74 pulmonary resections in patients with massive hemoptysis in the last 15 years, with a mortality of 13%. The mortality correlated with the rate and the amount of recorded blood loss before the operation. From this experience, we have identified a subgroup of patients with such massive hemoptysis that life was threatened by exsanguination. Twenty-four of our patients lost more than 1,000 ml of blood, at a rate of at least 150 ml an hour, before the pulmonary resection was performed. The bleeding site was always identified by bronchoscopy. All patients were treated by resection of the bleeding lung parenchyma. Several methods were used to avoid the patient's drowning in his own blood during the operation. In five patients, a double-lumen endotracheal tube was used: Two died of suffocation during the procedure and another died of respiratory and liver failure. In four patients, single-lung ventilation with an endotracheal tube in the left main bronchus was used: All four survived. In another 10 patients a bronchial blocker (No. 9 Fogarty balloon venous catheter) was used to stop bleeding. Two patients died of renal failure and gastrointestinal bleeding, respectively, but none had aspiration problems. In five additional patients, a regular endotracheal tube was used: One patient died of massive aspiration. Our experience indicates that bleeding from the left lung and right lower lobe should be controlled by intubation of the left bronchus. Patients with exsanguinating hemoptysis should be treated, when possible, by pulmonary resection. A survival rate of 75% was obtained in our patients.

Entities:  

Mesh:

Year:  1982        PMID: 7144217

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  9 in total

Review 1.  The pulmonary physician in critical care * Illustrative case 7: Assessment and management of massive haemoptysis.

Authors:  J L Lordan; A Gascoigne; P A Corris
Journal:  Thorax       Date:  2003-09       Impact factor: 9.139

Review 2.  A systematic approach to the management of massive hemoptysis.

Authors:  Christopher Radchenko; Abdul Hamid Alraiyes; Samira Shojaee
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

3.  Management of patients presenting with haemoptysis to a Tertiary Care Italian Emergency Department: the Florence Haemoptysis Score (FLHASc).

Authors:  Simone Vanni; Simone Bianchi; Sofia Bigiarini; Claudia Casula; Marco Brogi; Stefano Orsi; Manlio Acquafresca; Lorenzo Corbetta; Stefano Grifoni
Journal:  Intern Emerg Med       Date:  2017-02-03       Impact factor: 3.397

4.  Major hemoptysis in adolescents.

Authors:  Kin-sun Wong; Reyin Lien; Shao-Hsuan Hsia
Journal:  Indian J Pediatr       Date:  2005-06       Impact factor: 1.967

Review 5.  Massive hemoptysis.

Authors:  T W Noseworthy; B J Anderson
Journal:  CMAJ       Date:  1986-11-15       Impact factor: 8.262

6.  Double-lumen endobronchial tube in the emergency management of massive hemoptysis.

Authors:  Luciano Santana-Cabrera; Manuela Fernández Arroyo; Alina Uriarte Rodriguez; Manuel Sanchez-Palacios
Journal:  J Emerg Trauma Shock       Date:  2010-07

7.  The factors related to recurrence after transcatheter arterial embolization for the treatment of hemoptysis.

Authors:  K J Kim; J H Yoo; N C Sung; H S Won; K H Yoou; H M Kang
Journal:  Korean J Intern Med       Date:  1997-01       Impact factor: 2.884

8.  Idiopathic bronchial hemorrhage: a rare but catastrophic complication in cardiac surgery.

Authors:  Takeshi Uzuka; Masanori Nakamura; Tomohiro Nakajima; Shinichi Kusudoh; Hiroaki Usubuchi; Akihiko Tanaka; Noriyasu Watanabe
Journal:  J Cardiothorac Surg       Date:  2016-05-05       Impact factor: 1.637

Review 9.  Approach to Hemoptysis in the Modern Era.

Authors:  Sébastien Gagnon; Nicholas Quigley; Hervé Dutau; Antoine Delage; Marc Fortin
Journal:  Can Respir J       Date:  2017-12-21       Impact factor: 2.409

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.